Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer
Cancer Science · 2023
DOI: 10.1111/cas.15804 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2023. Verfasst von Jiatao Liao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International C…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Extracellular Vesicles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Project of China, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
Better biomarkers are needed to improve the efficacy of immune checkpoint inhibitors in lung adenocarcinoma (LUAD) treatment. We investigated the plasma extracellular vesicle (EV)‐derived long RNAs (exLRs) in unresectable/advanced LUAD to explore biomarkers for immunochemotherapy. Seventy‐four LUAD patients without targetable mutations receiving first‐line anti‐programmed cell death 1 (PD‐1) immunochemotherapy were enrolled. Their exLRs were profiled through plasma EV transcriptome sequencing. Biomarkers were analyzed against response rate and survival using pre‐ and post‐treatment samples in the retrospective cohort ( n = 36) and prospective cohort ( n = 38). The results showed that LUAD patients demonstrated a distinct exLR profile from the healthy individuals ( n = 56), and T‐cell activation‐related pathways were enriched in responders. Among T‐cell activation exLRs, CD160 exhibited a strong correlation with survival. In the retrospective cohort, the high baseline EV‐derived CD160 level correlated with prolonged progression‐free survival (PFS) ( P < 0.001) and overall survival (OS) ( P = 0.005), with an area under the curve (AUC) of 0.784 for differentiating responders from non‐responders. In the prospective cohort, the CD160‐high patients also showed prolonged PFS ( P = 0.003) and OS ( P = 0.014) and a promising AUC of 0.648. The predictive value of CD160 expression was validated by real‐time quantitative PCR. We also identified the dynamics of EV‐derived CD160 for monitoring therapeutic response. The elevated baseline CD160 reflected a higher abundance of circulating NK cells and CD8 + ‐naïve T cells, suggesting more active host immunity. In addition, increased CD160 levels of tumors also correlated with a favorable prognosis in LUAD patients. Together, plasma EV transcriptome analysis revealed the role of the baseline CD160 level and early post‐treatment CD160 dynamics for predicting the response to anti‐PD‐1 immunochemotherapy in LUAD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism, Institutes of Biom…
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Geneseeq Research Institute, Nanjing Geneseeq Technology., Nanjing, Jiangsu, China.
- Shanghai Key Laboratory of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Yan Li, Ying Lin, Jialei Wang
Förderung
- National Key Research and Development Project of China
- Shanghai Municipal Health Commission
Zitieren
APA
Liao, J., Lai, H., Liu, C., Zhang, X., Ou, Q., Li, Q., Li, Y., Wang, Z., Liu, C., Wu, X., Wang, H., Yu, H., Sun, S., Zhao, X., Hu, Z., Zhang, Y., Lin, Y., Yu, B., Huang, S., & Wang, J. (2023). Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer. Cancer Science. https://doi.org/10.1111/cas.15804
Vancouver
Liao J, Lai H, Liu C, Zhang X, Ou Q, Li Q, et al. Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer. Cancer Science. 2023. doi:10.1111/cas.15804
BibTeX
@article{Liao2023,
author = {Liao, Jiatao and Lai, Hongyan and Liu, Chang and Zhang, Xin and Ou, Qiuxiang and Li, Qiaojuan and Li, Yan and Wang, Zhen and Liu, Cuicui and Wu, Xianghua and Wang, Huijie and Yu, Hui and Sun, Si and Zhao, Xinmin and Hu, Zhihuang and Zhang, Yao and Lin, Ying and Yu, Bo and Huang, Shenglin and Wang, Jialei},
title = {Plasma extracellular vesicle transcriptomics identifies CD160 for predicting immunochemotherapy efficacy in lung cancer},
journal = {Cancer Science},
year = {2023},
doi = {10.1111/cas.15804}
}
EUVIMED